Celldex Therapeutics, Inc.
$34.38
▼
-0.64%
2026-04-21 06:04:00
www.celldex.com
NCM: CLDX
Explore Celldex Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.7 B
Current Price
$34.38
52W High / Low
$35.29 / $17.45
Stock P/E
—
Book Value
$7.92
Dividend Yield
—
ROCE
-54.02%
ROE
-40.62%
Face Value
—
EPS
$-3.9
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
198
Beta
1.2
Debt / Equity
0.44
Current Ratio
10.48
Quick Ratio
10.49
Forward P/E
-6.77
Price / Sales
1,637.31
Enterprise Value
$1.63 B
EV / EBITDA
-5.74
EV / Revenue
1,054.93
Rating
Strong Buy
Target Price
$54.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
| 2. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 3. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
| 4. | Prime Medicine, Inc. | $3.89 | — | $687.9 M | — | -68.25% | -1.47% | $6.94 / $1.11 | $0.68 |
| 5. | NovaBay Pharmaceuticals Inc | $1.4 | — | $51.92 M | 0% | -96.1% | 190.01% | $99.75 / $1.11 | $-0.92 |
| 6. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 7. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0.12 M | 0 M | 0.73 M | 0.69 M | 1.18 M |
| Operating Profit | -87.15 M | -73.62 M | -63.86 M | -62.74 M | -56.03 M |
| Net Profit | -81.32 M | -67.04 M | -56.6 M | -53.8 M | -47.09 M |
| EPS in Rs | -1.04 | -0.85 | -0.72 | -0.69 | -0.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.54 M | 7.02 M | 6.88 M | 2.36 M |
| Operating Profit | -287.37 M | -195.08 M | -142.04 M | -107.1 M |
| Net Profit | -258.76 M | -157.86 M | -141.43 M | -112.33 M |
| EPS in Rs | -3.3 | -2.01 | -1.8 | -1.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 582.98 M | 792.34 M | 465.63 M | 352.74 M |
| Total Liabilities | 55.82 M | 45.34 M | 36.46 M | 26.53 M |
| Equity | 527.16 M | 747 M | 429.17 M | 326.2 M |
| Current Assets | 534.66 M | 747.16 M | 431.69 M | 317.69 M |
| Current Liabilities | 50.99 M | 39.5 M | 31.12 M | 18.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -210.94 M | -157.78 M | -107.29 M | -103.73 M |
| Investing CF | 209.07 M | -290.13 M | -105.78 M | 89.94 M |
| Financing CF | 2.39 M | 441.45 M | 218.46 M | 4.08 M |
| Free CF | -213.66 M | -159.7 M | -109.11 M | -105.56 M |
| Capex | -2.71 M | -1.92 M | -1.82 M | -1.83 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 1.99% | 192.02% | — | — |
| Earnings Growth % | -11.62% | -25.91% | — | — |
| Profit Margin % | -2248.76% | -2054.76% | -4765.59% | — |
| Operating Margin % | -2778.89% | -2063.66% | -4543.74% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -2733.63% | -2019.96% | -4420.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.